# Esophageal-epidermoid-metaplasia
# 食管表皮样化生：从病例报告到癌前病变确立的研究进展与临床病理思考
作者：魏建华 广州华银医学检验中心 weijianhualai@gmail.com

## Abstract
Esophageal epidermoid metaplasia (EEM) represents a rare esophageal entity, the understanding of which has evolved from sporadic case reports to systematic investigations.This review systematically delineates the developmental trajectory of EEM, spanning from its initial case report in 1997 to its designation as a distinct precursor lesion in the 6th Edition of the WHO Classification of Digestive System Tumours in 2026. It focuses on elucidating the clinicopathological evidence, molecular mechanisms, diagnostic criteria, detection techniques, and management strategies regarding EEM as a precursor for esophageal squamous cell carcinoma (ESCC).Through an analysis of pivotal literature, this article explores existing knowledge gaps and future research directions, providing an evidence-based foundation for clinical and pathological practice.

## Keywords
Esophageal Epidermoid Metaplasia; Hyperorthokeratosis; Precursor lesion; Preneoplastic condition

## 摘要
食管表皮样化生（Esophageal Epidermoid Metaplasia, EEM）是一种罕见的食管病变，其认识经历了从个案报告到系统性研究的演变历程。本综述系统梳理了EEM从1997年首次病例报告至2026年被WHO第六版消化系统肿瘤分类单独列为癌前病变的发展脉络，重点阐述其作为食管鳞状细胞癌（Esophageal Squamous Cell Carcinoma, ESCC）癌前病变的临床病理证据、分子机制、诊断标准、检测技术及管理策略。通过对关键文献的分析，本文探讨了该领域存在的知识空白和未来研究方向，为临床病理实践提供循证依据。
## 关键词
食管表皮样化生，正角化过度，前驱病变，癌前状态

## 1. 引言
- 食管表皮样化生（EEM），亦称食管白斑（esophageal leukoplakia），是一种以食管鳞状上皮发生类似皮肤表皮样改变为特征的少见病变。其组织学特点包括上皮增生、基底层增厚、棘细胞层肥厚、显著颗粒层及表面正角化过度。该病变在口腔黏膜较为常见，与口腔鳞癌密切相关，但在食管的发生极为罕见，其临床意义长期未被充分认识。[1][2]
- 1997年，Nakanishi等首次详细报告了1例经Lugol染色检出的食管表皮样化生病例，开启了对该病变的系统研究。2014年，Singhi等对18例患者的临床病理研究发现，17%的患者伴发高级别鳞状上皮内瘤变或癌，首次提示EEM可能具有恶性转化潜能。2017年，同一团队通过靶向基因测序证实EEM与ESCC存在克隆相关性，并发现TP53突变可作为进展的预测标志。这些里程碑式研究逐步确立了EEM作为ESCC癌前病变的地位。[1][2][3]
- 本文旨在系统梳理EEM研究的演变历程，批判性分析现有证据，并提出该领域的知识缺陷和未来研究方向。
## 2. EEM的临床病理特征
### 2.1 流行病学与临床表现
- EEM是一种罕见的食管病变，其发生率显著低于口腔白斑。Cottreau等在1048例连续食管活检/切除标本中仅发现2例（0.19%），而Singhi等在三家学术中心6个月内198例连续食管活检中未发现任何病例，凸显其稀有性。[1][4]
- 患者年龄范围为37-81岁（平均61.5岁），女性略占优势（56%），这与口腔白斑以男性为主形成对比。主要临床症状为吞咽困难（56%）。危险因素包括吸烟或长期二手烟暴露（61%）和饮酒（39%），与ESCC危险因素部分重叠。[1][5]
- Kamboj等的40例系列研究揭示了EEM的重要临床特征：[6]23%的患者在EEM诊断前、同时或之后发生ESCC。此外，EEM与多种食管疾病相关，包括食管扁平苔藓（5例）、Barrett食管（7例）和食管腺癌（1例），提示慢性炎症和上皮损伤可能是共同病理基础。[6]
### 2.2 内镜特征
- EEM在常规白光内镜下易被漏诊。Kamboj等报告，[6]45%的EEM病例在既往内镜检查中未被发现，这与其微妙的内镜表现有关。病变可表现为局灶性（70%）或弥漫性（30%），主要位于食管中下段（94%）。[1]
- Lugol碘染色是检测EEM的关键技术。Nakanishi等首次证实Lugol染色可清晰显示EEM为不着色区域（Lugol unstained lesions, LULs），显著提高检出率。Dawsey等在中国林县高危人群研究中发现，Lugol染色将高级别上皮内瘤变和癌的检出敏感性从62%提高至96%。[2][7][8] 然而，Li等在中国高危地区15,264名居民的筛查研究中发现，Lugol染色对低级别上皮内瘤变的敏感性有限（45.9%），提示存在假阴性风险。[9]
### 2.3 组织病理学特征
- EEM的组织学诊断标准包括：
- 1.	边界清楚的上皮增生
- 2.	显著的颗粒层（prominent granular cell layer） —— 核心特征
- 3.	表面正角化过度（superficial hyperorthokeratosis）
- 4.	棘细胞层肥厚（acanthosis）
- 5.	基底层增厚

- 这些特征模拟皮肤表皮结构，与正常食管鳞状上皮明显不同。关键病理鉴别点在于：EEM主要表现为成熟异常（组织学描述强调了具有有序成熟特征的上皮增生：表现为基底层增厚、中间层棘层肥厚、明显的颗粒层以及表面过度正角化），而非定义异型增生的细胞异型性，这与鳞状上皮内瘤变形成鲜明对比。[1][10][11]

- **关键病理鉴别点：**
-- 与鳞状上皮内瘤变的区别：EEM主要表现为成熟异常（组织学描述强调了具有有序成熟特征的上皮增生：表现为基底层增厚、中间层棘层肥厚、明显的颗粒层以及表面过度正角化）而非异型增生（dysplasia），核异型性轻微，有序分层保留[1][10-11]
-- 与反应性改变的区别：EEM具有特征性颗粒层和正角化，边界清楚，而反应性增生通常弥漫，缺乏完整的表皮样分化。

### 2.4 免疫组织化学的价值
目前对EEM特异性免疫标志物的报道有限。Nakanishi等显示角蛋白染色可辅助诊断。相比之下，p53免疫组化在食管鳞状上皮内瘤变诊断中价值明确：[13]
- •	p53：Singhi等发现56%的EEM携带TP53突变。[3] 免疫组化显示的突变型表型（过表达或完全缺失）提示高风险。[26]
- •	Ki-67：强阳性表达通常提示伴发高级别上皮内瘤变。[30]
- •	新型标志物：CD71、Mcm2/5等在鉴别良恶性增生中显示出潜力，但需在EEM中进一步验证。[25][63]

## 3. EEM作为ESCC癌前病变的证据与机制
### 3.1 临床病理学证据
-**多项研究支持EEM与ESCC的关联：**
- 1.	患病率：Cottreau等发现，EEM在ESCC患者中的患病率（3.5%）显著高于对照组（0.19%），比值比为18.1。[4]
- 2.	并发风险：Singhi等报告17%的患者伴发高级别上皮内瘤变或ESCC；Kamboj等报告23%的患者发生ESCC。[1][6]
- 3.	持续性：54%的患者病变在随访期间持续存在。[1]
### 3.2 分子生物学证据
Singhi等的靶向测序研究提供了关键分子证据：[3]
— •	基因突变谱：67%（12/18）的EEM标本携带与ESCC相关的基因改变，最常见的是TP53突变（10/18，56%），其次是PIK3CA（2例）和EGFR突变（2例），MYCN、HRAS、TERT启动子突变各1例。
- •	克隆关系：EEM与伴发的高级别上皮内瘤变/ESCC共享相同的基因突变，在5例同时或异时发生高级别上皮内瘤变/ESCC的患者中，测序分析揭示两者存在共同的遗传改变，提示克隆演化关系。这类似于Barrett食管与食管腺癌的关系。[3]
### 3.3 分子机制推论
基于现有证据，EEM进展为ESCC的可能分子机制包括：
- 1.	早期事件：TP53双等位基因失活导致基因组不稳定，为后续改变铺路。[18][20]
- 2.	中期事件：PIK3CA、EGFR等致癌基因激活，促进细胞增殖。[3]
- 3.	晚期事件：拷贝数改变（CNAs）累积及APOBEC突变特征出现，最终导致浸润性癌变。[17]
### 3.4 野区癌化（Field Cancerization）与EEM
- EEM很可能是食管野区癌化的一种“可视标志”。野区癌化理论认为致癌物暴露导致大片黏膜发生早期遗传改变（如克隆性p53突变）。[67][70] EEM的多灶性特征、切除后的高复发率，以及与伴发癌共享突变的现象，均支持其作为广泛致癌野区中克隆扩增的局部表现。[1][3][22] Chang等最新的单细胞研究进一步揭示，晚期癌前病变通过重塑微环境（如募集成纤维细胞）来促进进展，EEM的基底细胞增生可能正是这一过程的早期形态。[71]

## 4. WHO第六版分类对EEM的影响与临床实践指导
### 4.1 WHO第六版的关键更新
Requena和Montgomery在2025年的综述中详细解读了WHO第六版消化系统肿瘤分类的更新要点，[72]其中最具里程碑意义的变化是食管表皮样化生（EEM）被正式单独列为一个章节，作为食管癌前病变进行独立介绍。这一变化不仅反映了术语简化的总体趋势，更标志着EEM的临床地位从“罕见良性病变”向“确定的癌前病变”发生了根本性转变。[72][73][74]
### 4.2 病理诊断体系的演变
- 1.	第五版（2019）：[73]上皮内瘤变仅简单划分为Barrett相关和鳞状上皮相关（低级别/高级别），EEM未被提及，导致其在临床实践中常被归类为非特异性增生。
- 2.	第六版（2026）：[72]EEM作为独立章节与鳞状上皮内瘤变并列。这一修订整合了过去10年积累的分子（TP53突变）和临床（进展风险）证据，强调了其独特的生物学行为。
### 4.3 对临床实践的指导意义
•	诊断层面：病理医师需熟悉EEM的“指纹特征”（显著颗粒层和正角化），并按照新标准在报告中明确使用“食管表皮样化生”术语，而非描述性的“白斑”。[1][2][72]
•	管理层面：提升了内镜医师对Lugol不着色区的警惕性，促进了多学科（MD）协作，推动了分子检测结果（如p53）在个体化治疗中的转化应用。[1][24]

## 5. 诊断标准与检测技术
### 5.1 组织学鉴别诊断
- 为了直观区分EEM与上皮内瘤变，避免误诊，表2总结了关键鉴别特征：
**表2. EEM与食管鳞状上皮内瘤变的组织学特征比较**
特征	EEM	低级别上皮内瘤变 (LGIN)	高级别上皮内瘤变 (HGIN)	参考文献
核异型性	轻微	轻至中度	显著	[1][2][4]
分层有序性	保留	保留	部分或完全丧失	[2][4]
颗粒层	显著 (Prominent)	缺如或不明显	缺如	[1][2][3]
角化	表面正角化过度	无或轻微	无或异常角化	[1][2][3]
棘细胞层	显著增厚	正常或轻度增厚	可变	[1][2][3]
主要异常	成熟异常	轻度典型增生	显著典型增生	[1][10][11]
### 5.2 误诊陷阱与报告建议
- 形态学差异可能导致EEM被误诊为反应性改变（因核异型性轻微）或低级别上皮内瘤变（因基底层增厚）。[1][2] 根据NCCN指南及EEM的特殊性，建议病理报告：
1.	明确术语：使用“食管表皮样化生”而非模糊的“角化过度”。
2.	分层评估：明确指出是否伴发上皮内瘤变或癌。
3.	建议复审：疑诊上皮内瘤变的病例应由第二位胃肠病理专家复审。[24]

## 6. EEM的治疗与管理策略
### 6.1 治疗策略
目前缺乏EEM特异性治疗指南，临床管理主要借鉴食管鳞状上皮内瘤变的治疗经验。根据NCCN指南和相关共识，治疗选择应基于病变特征和恶性转化风险：[24][49]
- 1.	伴发上皮内瘤变/癌的EEM：首选内镜切除。
-- o	ESD（内镜黏膜下剥离术）：适用于病灶>15 mm或环周性病变。Ding等研究显示，对于环周病变，ESD结合牵引技术可实现更完整的整块切除（92.3% vs 52.7%），尽管狭窄风险略高。[54]
-- o	EMR（内镜黏膜切除术）：适用于<15 mm的局灶性病变。
- 2.	单纯EEM（无上皮内瘤变）：
-- o	高危组：若TP53突变阳性或其他高危分子标志物存在，建议积极干预（切除或消融）。
-- o	低危组：若无高危分子标志物，可考虑密切内镜监测。
- 3.	多灶性/广泛病变：
-- o	若病灶广泛，**射频消融（RFA）**是有效选择。Cheng等的Meta分析显示，RFA治疗早期食管鳞状细胞肿瘤的12个月完全缓解率达83%。[55] 对于环周病变，RFA比ESD具有更低的狭窄率（31% vs 60%）。[54]
### 6.2 内镜监测与随访策略
鳞状上皮内瘤变的监测参照
根据NCCN 2025年指南，Tis或T1a病变治疗后：[24]
- •	第1年：每3个月1次。
- •	第2年：每6个月1次。
- •	第3年及以后：每年1次，终身监测。
**关键技术：**
综合运用Lugol碘染色（识别不着色区）、NBI（评估血管模式）及放大内镜。
**EEM的监测策略（建议）**
鉴于EEM与低级别上皮内瘤变的相似性及潜在风险（年进展率约1%-5%），[60][65] 提出以下分层监测方案：
**1.	初次发现EEM：**
- o	全食管Lugol染色评估，识别多发病灶。
- o	充分活检排除隐匿的伴发癌。
**关键步骤** 评估TP53突变状态（如技术可及）。
**2.	单纯EEM（无上皮内瘤变）：**
- o	第1年：3-6个月复查1次（旨在排除初次内镜漏诊的同时性病变）。
- o	第2-3年：每6-12个月1次。
- o	第4年及以后：每年1次。
**注**：TP53突变阳性者应始终采用更密集的监测频率。
**3.	EEM伴上皮内瘤变/癌**：严格参照相应级别的鳞状上皮内瘤变或癌的监测方案。[24]
- 监测终止条件：当患者预期寿命有限、无法耐受后续治疗，或连续多次检查无进展且无高危因素时，可个体化决定终止监测。

## 7. 人工智能与数字病理在EEM中的应用前景
### 7.1 内镜AI辅助检测
目前，AI在食管鳞状上皮内瘤变和ESCC检测中已显示出色表现。Li等的前瞻性随机对照研究显示，[75]深度学习辅助内镜将高危食管病变检出率提高了一倍（1.8% vs 0.9%, P=0.029），系统的敏感性、特异性和准确性分别为89.7%、98.5%和98.2%。
对于EEM，AI的潜在应用场景包括：[75][76][77]
- 1.	实时检测：自动识别Lugol不着色区域中的EEM特征性表现，减少漏诊。
- 2.	病灶定位与标注：绘制边界框，引导活检部位选择。
- 3.	鉴别诊断支持：辅助区分EEM与其他Lugol不着色病变（如炎症或低级别上皮内瘤变）。
### 7.2 病理AI辅助诊断
在Barrett食管上皮内瘤变诊断中，AI已展示出超越人类病理医师的表现。Botros等开发的深度学习系统在评估55张全切片图像（WSI）时，[80]准确率达76.4%，超过了55名病理医师中的53名。
对于EEM，病理AI模型有望实现：[80][81]
- 1.	特征量化：客观测量颗粒层厚度、角化程度和核异型性评分。
- 2.	辅助分级：整合组织学特征，辅助病理医师进行良恶性鉴别。
- 3.	预后预测：结合分子数据（如p53表达），预测EEM的进展风险。
### 7.3 挑战与解决方案
尽管前景广阔，AI在EEM中的应用仍面临训练数据不足（EEM病例罕见）和标注质量（依赖专家经验）的挑战。建立国际共享的EEM病理图像数据库，并开发可解释性AI模型，是未来的关键突破口。[85][86]
## 8. 知识缺陷与未来研究方向
### 8.1 当前知识空白
尽管EEM的癌前地位已确立，但仍存在显著的证据缺口：
- 1.	自然史不明：现有数据多来自横断面研究（如Singhi和Kamboj），[1][6]缺乏长期前瞻性队列数据，导致EEM的终生癌变风险和中位进展时间未知。
- 2.	分子全景缺失：现有研究多基于靶向测序，缺乏全基因组/全外显子测序数据；表观遗传（如甲基化）和非编码RNA在EEM中的作用尚属空白。[3]
- 3.	诊断一致性未评估：鳞状上皮内瘤变的病理诊断一致性已知较差（κ=0.35），[62]但EEM的诊断一致性尚未被系统评估。
### 8.2 未来研究蓝图
为解决上述问题，建议开展以下方向的研究：
- 1.	建立国际多中心注册登记系统：招募至少500例EEM患者，进行至少10年的纵向随访，以明确其自然史和危险因素。[1]
- 2.	多组学与空间生物学研究：
-- o	利用单细胞RNA测序（scRNA-seq）解析EEM的细胞异质性。[71][79]
-- o	应用空间转录组学揭示CAF-上皮生态位等微环境变化，阐明EEM作为野区癌化标志的生物学基础。[71]
-- o	通过蛋白质组学寻找早期预警信号（如Li X等2026年发现的信号）。[78]
3.	精准管理策略的验证：开展随机对照试验（RCT），比较“TP53指导下的积极干预”与“常规监测”在单纯EEM患者中的长期收益（如无进展生存期）。[20][22]
## 9. 结论
食管表皮样化生（EEM）从1997年的单一病例报告，到2026年被WHO第六版分类正式确认为癌前病变，这一认识的演变体现了循证医学和精准医学的巨大进步。
主要结论如下：
1.	性质确立：EEM不再是良性病变，而是明确的癌前病变，具有17%-23%的恶性伴发率。[1][6]
2.	分子特征：TP53突变是其核心驱动事件，提示其与ESCC共享克隆起源。[3]
3.	诊断核心：显著颗粒层和表面正角化是病理诊断的基石。
4.	管理策略：单纯EEM需密切监测，伴发上皮内瘤变者应行内镜切除，TP53突变可作为激进治疗的参考依据。
未来的临床实践应强调基于组织学特征的准确诊断、基于分子病理的分层管理，以及内镜与病理的紧密协作。基于此，方能实现对这一特殊癌前病变的精准防控，最终降低食管鳞癌的发病率和死亡率。
## 致谢
本综述基于1997年至2026年的关键文献撰写，特别感谢Nakanishi、Singhi、Kamboj等研究团队的开创性工作，为EEM的认识奠定了坚实基础。同时感谢WHO专家组将EEM纳入第六版分类，为临床实践提供了国际标准。
## 利益冲突声明
作者声明无利益冲突。
## 作者贡献
本文为单一作者独立撰写的综述性文章，负责文献检索、数据分析及执笔撰写。
## 参考文献
1.	Esophageal Leukoplakia or Epidermoid Metaplasia: A Clinicopathological Study of 18 Patients. Singhi AD, Arnold CA, Crowder CD, et al. Modern Pathology. 2014;27(1):38-43. doi:10.1038/modpathol.2013.100.
2.	Epidermization in the Esophageal Mucosa: Unusual Epithelial Changes Clearly Detected by Lugol's Staining. Nakanishi Y, Ochiai A, Shimoda T, et al. The American Journal of Surgical Pathology. 1997;21(5):605-9. doi:10.1097/00000478-199705000-00015.
3.	Targeted Next-Generation Sequencing Supports Epidermoid Metaplasia of the Esophagus as a Precursor to Esophageal Squamous Neoplasia. Singhi AD, Arnold CA, Lam-Himlin DM, et al. Modern Pathology. 2017;30(11):1613-1621. doi:10.1038/modpathol.2017.73.
4.	Prevalence of Oesophageal Epidermoid Metaplasia in 1048 Consecutive Patients and 58 Patients With Squamous Neoplasms. Cottreau J, Gruchy S, Kamionek M, Lauwers GY, Arnason T. Histopathology. 2016;68(7):988-95. doi:10.1111/his.12886.
5.	Oesophageal Cancer. Yang H, Wang F, Hallemeier CL, Lerut T, Fu J. Lancet (London, England). 2024;404(10466):1991-2005. doi:10.1016/S0140-6736(24)02226-8.
6.	Esophageal Epidermoid Metaplasia: Clinical Characteristics and Risk of Esophageal Squamous Neoplasia. Kamboj AK, Gibbens YY, Hagen CE, et al. The American Journal of Gastroenterology. 2021;116(7):1533-1536. doi:10.14309/ajg.0000000000001225.
7.	Mucosal Iodine Staining Improves Endoscopic Visualization of Squamous Dysplasia and Squamous Cell Carcinoma of the Esophagus in Linxian, China. Dawsey SM, Fleischer DE, Wang GQ, et al. Cancer. 1998;83(2):220-31.
8.	The Significance of a Pale Area via Flexible Spectral Imaging Color Enhancement in the Diagnosis of Esophageal Precancerous Lesions and Early-Stage Squamous Cancer. Li Y, Yangjin C, Shi Y, et al. Journal of Clinical Gastroenterology. 2019;53(9):e400-e404. doi:10.1097/MCG.0000000000001191.
9.	Lugol Chromoendoscopy Detects Esophageal Dysplasia With Low Levels of Sensitivity in a High-Risk Region of China. Li J, Xu R, Liu M, et al. Clinical Gastroenterology and Hepatology. 2018;16(10):1585-1592. doi:10.1016/j.cgh.2017.11.031.
10.	Squamous Neoplasia in the Esophagus. Savant D, Zhang Q, Yang Z. Archives of Pathology & Laboratory Medicine. 2021;145(5):554-561. doi:10.5858/arpa.2020-0058-RA.
11.	Squamous Neoplastic Precursor Lesions of the Esophagus. Arai T, Ono S, Takubo K. Gastroenterology Clinics of North America. 2024;53(1):25-38. doi:10.1016/j.gtc.2023.09.004.
12.	Refinement and Reproducibility of Histologic Criteria for the Assessment of Microscopic Lesions in Patients With Gastroesophageal Reflux Disease: The Esohisto Project. Yerian L, Fiocca R, Mastracci L, et al. Digestive Diseases and Sciences. 2011;56(9):2656-65. doi:10.1007/s10620-011-1624-z.
13.	AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus. Wani S, Zhou MJ, Sawas T, et al. Gastroenterology. 2025;169(6):1184-1231. doi:10.1053/j.gastro.2025.09.012.
14.	Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus. Grady WM, Yu M. Digestive Diseases and Sciences. 2018;63(8):2059-2069. doi:10.1007/s10620-018-5090-8.
15.	Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma Sequence in the Esophagus. Jankowski JA, Wright NA, Meltzer SJ, et al. The American Journal of Pathology. 1999;154(4):965-73. doi:10.1016/S0002-9440(10)65346-1.
16.	Overview of Major Molecular Alterations During Progression From Barrett's Esophagus to Esophageal Adenocarcinoma. Kalatskaya I. Annals of the New York Academy of Sciences. 2016;1381(1):74-91. doi:10.1111/nyas.13134.
17.	Genomic Instability Is Widespread in Esophageal Squamous Dysplasia and Increases During the Progression to Cancer. An H, Cheng X, Xue L, et al. Frontiers in Bioscience (Landmark Edition). 2025;30(10):41107. doi:10.31083/FBL41107.
18.	Genomic Alterations Driving Precancerous to Cancerous Lesions in Esophageal Cancer Development. Chang J, Zhao X, Wang Y, et al. Cancer Cell. 2023;41(12):2038-2050.e5. doi:10.1016/j.ccell.2023.11.003.
19.	Genetic Alterations in Esophageal Tissues From Squamous Dysplasia to Carcinoma. Liu X, Zhang M, Ying S, et al. Gastroenterology. 2017;153(1):166-177. doi:10.1053/j.gastro.2017.03.033.
20.	Extremely Early Genomic Events and Temporal Order of Esophageal Squamous Cell Carcinogenesis: Longitudinal Self-Comparison of Progressors and Non-Progressors. Liu Y, Liu M, Yang Y, et al. American Journal of Human Genetics. 2025;:S0002-9297(25)00239-3. doi:10.1016/j.ajhg.2025.06.008.
21.	Molecular Abnormalities and Carcinogenesis in Barrett's Esophagus: Implications for Cancer Treatment and Prevention. de Melo Viana TC, Nakamura ET, Park A, et al. Genes. 2025;16(3):270. doi:10.3390/genes16030270.
22.	Targeted Genetic and Epigenetic Profiling of Esophageal Adenocarcinomas and Non-Dysplastic Barrett's Esophagus. Pinto R, Hauge T, Jeanmougin M, et al. Clinical Epigenetics. 2022;14(1):77. doi:10.1186/s13148-022-01287-7.
23.	Oesophageal Hyperkeratosis: Clinicopathological Associations. Taggart MW, Rashid A, Ross WA, Abraham SC. Histopathology. 2013;63(4):463-73. doi:10.1111/his.12195.
24.	Esophageal and Esophagogastric Junction Cancers. National Comprehensive Cancer Network (NCCN). Updated 2025-12-10.
25.	CD71 in Tandem With Ki-67 and P53: Unraveling Their Prognostic and Diagnostic Significance in Esophageal Squamous Cell Carcinoma and Precursor Lesions. Huang C, Tao L, Ma X, Zhang Z, Su M. Applied Immunohistochemistry & Molecular Morphology. 2025;:00129039-990000000-00245. doi:10.1097/PAI.0000000000001283.
26.	Use of Immunohistochemical P53 Mutant-Phenotype in Diagnosis of High-Grade Dysplasia of Esophageal Squamous Epithelia. Xu YJ, Li R, Chen JM, et al. Digestive Diseases. 2023;41(5):685-694. doi:10.1159/000531331.
27.	P53 Expression in Squamous Dysplasia Associated With Carcinoma of the Oesophagus: Evidence for Field Carcinogenesis. Yasuda M, Kuwano H, Watanabe M, et al. British Journal of Cancer. 2000;83(8):1033-8. doi:10.1054/bjoc.2000.1443.
28.	Biomarker Risk Stratification With Capsule Sponge in the Surveillance of Barrett's Oesophagus: Prospective Evaluation of UK Real-World Implementation. Tan WK, Ross-Innes CS, Somerset T, et al. Lancet (London, England). 2025;406(10500):271-282. doi:10.1016/S0140-6736(25)01021-9.
29.	Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Shaheen NJ, Falk GW, Iyer PG, et al. The American Journal of Gastroenterology. 2022;117(4):559-587. doi:10.14309/ajg.0000000000001680.
30.	Ki-67 and ProExC Are Useful Immunohistochemical Markers in Esophageal Squamous Intraepithelial Neoplasia. Wang WC, Wu TT, Chandan VS, Lohse CM, Zhang L. Human Pathology. 2011;42(10):1430-7. doi:10.1016/j.humpath.2010.12.009.
31.	Upper Aerodigestive Tract Squamous Dysplasia: Correlation With P16, P53, pRb, and Ki-67 Expression. Wayne S, Robinson RA. Archives of Pathology & Laboratory Medicine. 2006;130(9):1309-14. doi:10.5858/2006-130-1309-UATSDC.
32.	Loss of P16 and High Ki67 Labeling Index Is Associated With Poor Outcome in Esophageal Carcinoma. Jacobsen F, Kohsar J, Gebauer F, et al. Oncotarget. 2020;11(12):1007-1016. doi:10.18632/oncotarget.27507.
33.	P16 in Highly Malignant Esophageal Carcinomas: The Correlation With Clinicopathological Factors and Human Papillomavirus Infection. Ishida H, Kasajima A, Fujishima F, et al. Virchows Archiv. 2021;478(2):219-229. doi:10.1007/s00428-020-02865-x.
34.	Stepwise Expression of CDKN2A and RB1 Proteins in Esophageal Mucosa From Patients at High Risk for Squamous Cell Carcinoma. Müller LB, Meurer L, Lopes AB, et al. Applied Immunohistochemistry & Molecular Morphology. 2014;22(9):669-73. doi:10.1097/PAI.0000000000000011.
35.	Topological Analysis of P21waf1/Cip1 Expression in Esophageal Squamous Dysplasia. Shirakawa Y, Naomoto Y, Kimura M, et al. Clinical Cancer Research. 2000;6(2):541-50.
36.	Expression of Cell Cycle Regulatory Proteins in the Multistep Process of Oesophageal Carcinogenesis: Stepwise Over-Expression of Cyclin E and P53, Reduction of P21(waf1/Cip1) and Dysregulation of Cyclin D1 and P27(KIP1). Ohbu M, Kobayashi N, Okayasu I. Histopathology. 2001;39(6):589-96. doi:10.1046/j.1365-2559.2001.01279.x.
37.	Alterations of P53, Cyclin D1 and pRB Expression in the Carcinogenesis of Esophageal Squamous Cell Carcinoma. Kawakubo H, Ozawa S, Ando N, et al. Oncology Reports. 2005;14(6):1453-9. doi:10.3892/or.14.6.1453.
38.	Γ-Glutamylcyclotransferase as a Novel Immunohistochemical Biomarker for the Malignancy of Esophageal Squamous Tumors. Takemura K, Kawachi H, Eishi Y, et al. Human Pathology. 2014;45(2):331-41. doi:10.1016/j.humpath.2013.09.009.
39.	The Discovery and Validation of Biomarkers for the Diagnosis of Esophageal Squamous Dysplasia and Squamous Cell Carcinoma. Couch G, Redman JE, Wernisch L, et al. Cancer Prevention Research (Philadelphia, Pa.). 2016;9(7):558-66. doi:10.1158/1940-6207.CAPR-15-0379.
40.	Narrow-Band Imaging Versus Lugol Chromoendoscopy for Esophageal Squamous Cell Cancer Screening in Normal Endoscopic Practice: Randomized Controlled Trial. Gruner M, Denis A, Masliah C, et al. Endoscopy. 2021;53(7):674-682. doi:10.1055/a-1224-6822.
41.	Usefulness of Non-Magnifying Narrow-Band Imaging in Screening of Early Esophageal Squamous Cell Carcinoma: A Prospective Comparative Study Using Propensity Score Matching. Nagami Y, Tominaga K, Machida H, et al. The American Journal of Gastroenterology. 2014;109(6):845-54. doi:10.1038/ajg.2014.94.
42.	Narrow Band Imaging Versus Lugol Chromoendoscopy to Diagnose Squamous Cell Carcinoma of the Esophagus: A Systematic Review and Meta-Analysis. Morita FH, Bernardo WM, Ide E, et al. BMC Cancer. 2017;17(1):54. doi:10.1186/s12885-016-3011-9.
43.	Narrow-Band Imaging Without Magnification for Detecting Early Esophageal Squamous Cell Carcinoma. Ide E, Maluf-Filho F, Chaves DM, Matuguma SE, Sakai P. World Journal of Gastroenterology. 2011;17(39):4408-13. doi:10.3748/wjg.v17.i39.4408.
44.	Current Status of Endoscopic Detection, Characterization and Staging of Superficial Esophageal Squamous Cell Carcinoma. Ishihara R, Muto M. Japanese Journal of Clinical Oncology. 2022;52(8):799-805. doi:10.1093/jjco/hyac064.
45.	Clinicopathological Features of Narrow-Band Imaging Endoscopy and Immunohistochemistry in Ultraminute Esophageal Squamous Neoplasms. Goda K, Dobashi A, Yoshimura N, et al. Diseases of the Esophagus. 2014;27(3):267-75. doi:10.1111/dote.12090.
46.	Endoscopic Diagnosis of Early Neoplasia of the Esophagus With Narrow Band Imaging: Correlations Among Background Coloration and Iodine Staining Findings. Takahashi M, Shimizu Y, Ono M, et al. Journal of Gastroenterology and Hepatology. 2014;29(4):762-8. doi:10.1111/jgh.12477.
47.	Simplified Criteria for Diagnosing Superficial Esophageal Squamous Neoplasms Using Narrow Band Imaging Magnifying Endoscopy. Dobashi A, Goda K, Yoshimura N, et al. World Journal of Gastroenterology. 2016;22(41):9196-9204. doi:10.3748/wjg.v22.i41.9196.
48.	Curriculum for Optical Diagnosis of Esophageal Neoplasia and Precursor Lesions: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Pouw RE, Weusten BLAM, Bergman JJHGM, et al. Endoscopy. 2025. doi:10.1055/a-2662-7978.
49.	ASGE Guideline on Endoscopic Submucosal Dissection for the Management of Early Esophageal and Gastric Cancers: Summary and Recommendations. Forbes N, Elhanafi SE, Al-Haddad MA, et al. Gastrointestinal Endoscopy. 2023;98(3):271-284. doi:10.1016/j.gie.2023.03.015.
50.	AGA Clinical Practice Update on Surveillance After Pathologically Curative Endoscopic Submucosal Dissection of Early Gastrointestinal Neoplasia in the United States: Commentary. Wang AY, Hwang JH, Bhatt A, Draganov PV. Gastroenterology. 2021;161(6):2030-2040.e1. doi:10.1053/j.gastro.2021.08.058.
51.	Radiofrequency Ablation for the Endoscopic Eradication of Esophageal Squamous High Grade Intraepithelial Neoplasia and Mucosal Squamous Cell Carcinoma. van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Endoscopy. 2011;43(4):282-90. doi:10.1055/s-0030-1256309.
52.	Extension of Early Esophageal Squamous Cell Neoplasia Into Ducts and Submucosal Glands and the Role of Endoscopic Ablation Therapy. Overwater A, van Munster SN, Offerhaus GJA, et al. Gastrointestinal Endoscopy. 2021;94(4):832-842.e2. doi:10.1016/j.gie.2021.04.028.
53.	Safety and Efficacy of Endoscopic Treatment With Mucosal Resection, Radiofrequency Ablation, and Cryotherapy in the Curative Treatment of Early Esophageal Squamous Cell Cancer and Dysplasia. Naz S, Elhariri A, Qiao W, et al. Journal of Clinical Oncology. 2025;43(Suppl 16):4055. doi:10.1200/JCO.2025.43.16_suppl.4055.
54.	Comparison Between ESD and RFA in Patients With Total or Near-Total Circumferential Early Esophageal Squamous Cell Neoplasia. Ding Y, Liu Y, Lei S, et al. Surgical Endoscopy. 2023;37(9):6915-6921. doi:10.1007/s00464-023-10178-8.
55.	Systematic Review and Meta-Analysis: The Efficacy and Safety of Radiofrequency Ablation for Early Superficial Esophageal Squamous Cell Neoplasia. Cheng HE, Shiu SI, Ko CW. BMC Gastroenterology. 2024;24(1):152. doi:10.1186/s12876-024-03250-7.
56.	Cryotherapy in the Management of Premalignant and Malignant Conditions of the Esophagus. Lal P, Thota PN. World Journal of Gastroenterology. 2018;24(43):4862-4869. doi:10.3748/wjg.v24.i43.4862.
57.	Depth-Oriented Organ-Preserving Salvage Endoscopic Strategy With Argon Plasma Coagulation and Photodynamic Therapy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Chemoradiotherapy. Fukagawa N, Furue Y, Katada C, et al. Japanese Journal of Clinical Oncology. 2026:hyaf221. doi:10.1093/jjco/hyaf221.
58.	Feasibility and Efficacy of Argon Plasma Coagulation for Early Esophageal Squamous Cell Neoplasia. Min BH, Kim ER, Lee JH, et al. Endoscopy. 2013;45(7):575-8. doi:10.1055/s-0033-1344025.
59.	Long-term Incidence Rates of Esophageal Squamous Cell Carcinoma in Chinese Patients With Low-grade Intraepithelial Neoplasia and Association of Surveillance Endoscopy With Incidence. Li H, Wu H, Cao M, et al. JAMA Network Open. 2022;5(12):e2247415. doi:10.1001/jamanetworkopen.2022.47415.
60.	Increased Risk of Esophageal Squamous Cell Carcinoma in Patients With Squamous Dysplasia: A Nationwide Cohort Study in the Netherlands. van Tilburg L, Spaander MCW, Bruno MJ, et al. Diseases of the Esophagus. 2023;36(12):doad045. doi:10.1093/dote/doad045.
61.	Endoscopic Surveillance for Premalignant Esophageal Lesions: A Community-Based Multicenter, Prospective Cohort Study. Li H, Zhang S, Zhou J, et al. Clinical Gastroenterology and Hepatology. 2023;21(3):653-662.e8. doi:10.1016/j.cgh.2022.04.039.
62.	An International Inter-Rater Agreement Study in the Challenging Diagnosis of Squamous Dysplasia of the Oesophagus. Patil A, Jiezhen TL, Kosiorek H, et al. Histopathology. 2025. doi:10.1111/his.15509.
63.	Aberrant Expression of Minichromosome Maintenance Proteins 2 and 5, and Ki-67 in Dysplastic Squamous Oesophageal Epithelium and Barrett's Mucosa. Going JJ, Keith WN, Neilson L, et al. Gut. 2002;50(3):373-7. doi:10.1136/gut.50.3.373.
64.	Long-Term Outcomes of Surveillance Endoscopy After Endoscopic Resection for Early Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Study. Dobashi A, Yoshio T, Minamide T, et al. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70226.
65.	Esophageal Histological Precursor Lesions and Subsequent 8.5-Year Cancer Risk in a Population-Based Prospective Study in China. Wei WQ, Hao CQ, Guan CT, et al. The American Journal of Gastroenterology. 2020;115(7):1036-1044. doi:10.14309/ajg.0000000000000640.
66.	Long-Term Esophageal Cancer Risk and Distinct Surveillance Intervals After a Single Endoscopy Screening: A Multicentre Population-Based Cohort Study. Li H, Xia C, He S, et al. EClinicalMedicine. 2023;63:102201. doi:10.1016/j.eclinm.2023.102201.
67.	A Genetic Explanation of Slaughter's Concept of Field Cancerization: Evidence and Clinical Implications. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. Cancer Research. 2003;63(8):1727-30.
68.	Genetic Steps in the Development of Squamous Cell Carcinoma of the Esophagus. Mandard AM, Hainaut P, Hollstein M. Mutation Research. 2000;462(2-3):335-42. doi:10.1016/s1383-5742(00)00019-3.
69.	Multifocal Accumulation of P53 Protein in Esophageal Carcinoma: Evidence for Field Cancerization. Tian D, Feng Z, Hanley NM, et al. International Journal of Cancer. 1998;78(5):568-75. doi:10.1002/(sici)1097-0215(19981123)78:5<568::aid-ijc7>3.0.co;2-3.
70.	Field Cancerisation and Polyclonal P53 Mutation in the Upper Aero-Digestive Tract. Waridel F, Estreicher A, Bron L, et al. Oncogene. 1997;14(2):163-9. doi:10.1038/sj.onc.1200812.
71.	Single-Cell Multi-Stage Spatial Evolutional Map of Esophageal Carcinogenesis. Chang J, Lu J, Liu Q, et al. Cancer Cell. 2025;43(3):380-397.e7. doi:10.1016/j.ccell.2025.02.009.
72.	What's New in Upper Gastrointestinal Pathology: Key Updates and Evolving Challenges in 2026. Requena DO, Montgomery EA. Human Pathology. 2025:106025. doi:10.1016/j.humpath.2025.106025.
73.	Updates on World Health Organization Classification and Staging of Esophageal Tumors: Implications for Future Clinical Practice. Lam AK. Human Pathology. 2021;108:100-112. doi:10.1016/j.humpath.2020.10.015.
74.	Diagnosis of Digestive System Tumours. Washington MK, Goldberg RM, Chang GJ, et al. International Journal of Cancer. 2021;148(5):1040-1050. doi:10.1002/ijc.33210.
75.	Deep Learning Assists Detection of Esophageal Cancer and Precursor Lesions in a Prospective, Randomized Controlled Study. Li SW, Zhang LH, Cai Y, et al. Science Translational Medicine. 2024;16(743):eadk5395. doi:10.1126/scitranslmed.adk5395.
76.	Artificial Intelligence Applications in Image-Based Diagnosis of Early Esophageal and Gastric Neoplasms. Ebigbo A, Messmann H, Lee SH. Gastroenterology. 2025:S0016-5085(25)00471-8. doi:10.1053/j.gastro.2025.01.253.
77.	Artificial Intelligence and Deep Learning for Upper Gastrointestinal Neoplasia. Sharma P, Hassan C. Gastroenterology. 2022;162(4):1056-1066. doi:10.1053/j.gastro.2021.11.040.
78.	Spatio-Temporal Proteomic Landscape Reveals Early Warning Signals of Esophageal Squamous Cell Carcinoma Progression. Li X, Yuan J, Gao M, et al. Advanced Science. 2026:e14343. doi:10.1002/advs.202514343.
79.	Deciphering Precursor Cell Dynamics in Esophageal Preneoplasia via Genetic Barcoding and Single-Cell Transcriptomics. Jang J, Ko KP, Zhang J, Jun S, Park JI. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(49):e2509534122. doi:10.1073/pnas.2509534122.
80.	Deep Learning for Histopathological Assessment of Esophageal Adenocarcinoma Precursor Lesions. Botros M, de Boer OJ, Cardenas B, et al. Modern Pathology. 2024;37(8):100531. doi:10.1016/j.modpat.2024.100531.
81.	Development of a Deep Learning Model for the Histologic Diagnosis of Dysplasia in Barrett's Esophagus. Faghani S, Codipilly DC, Vogelsang D, et al. Gastrointestinal Endoscopy. 2022;96(6):918-925.e3. doi:10.1016/j.gie.2022.06.013.
82.	Absence of NOTCH1 Mutation and Presence of CDKN2A Deletion Predict Progression of Esophageal Lesions. Liu M, Liu Y, Zhou R, et al. The Journal of Pathology. 2022;258(1):38-48. doi:10.1002/path.5970.
83.	Identification of Novel Circulating miRNA Biomarkers for the Diagnosis of Esophageal Squamous Cell Carcinoma and Squamous Dysplasia. Shen Y, Ding Y, Ma Q, et al. Cancer Epidemiology, Biomarkers & Prevention. 2019;28(7):1212-1220. doi:10.1158/1055-9965.EPI-18-1199.
84.	Novel Devices and Biomarkers in Screening for Esophageal Squamous Cell Cancer. Januszewicz W, Nowicki-Osuch K. Best Practice & Research. Clinical Gastroenterology. 2025;75:102005. doi:10.1016/j.bpg.2025.102005.
85.	Deep Learning Systems Detect Dysplasia With Human-Like Accuracy Using Histopathology and Probe-Based Confocal Laser Endomicroscopy. Guleria S, Shah TU, Pulido JV, et al. Scientific Reports. 2021;11(1):5086. doi:10.1038/s41598-021-84510-4.
86.	Recent Advances in Machine Learning for Precision Diagnosis and Treatment of Esophageal Disorders. Liu SW, Li P, Li XQ, et al. World Journal of Gastroenterology. 2025;31(23):105076. doi:10.3748/wjg.v31.i23.105076.

<img width="415" height="692" alt="image" src="https://github.com/user-attachments/assets/1fb5e167-5ac2-4552-91b0-3da7706474e0" />
